AGIO vs ANL: fair value comparison
Agios Pharmaceuticals, Inc. and Adlai Nortye Group Ltd. · Updated 2026-10-19
AGIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ANL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AGIO currently ranks higher by quality score.
| AGIO | ANL | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $31.32 | $11.03 |
| 12-month range | $22.34–$45.49 | $0.88–$16.60 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #93 of 301 Healthcare | #94 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: AGIO fair value analysis · ANL fair value analysis